Executive Briefing Series (formerly The Food & Drug Letter)

An FDA warning that Merck could face fines for being months late on two postmarket study deadlines appears to be the first time the FDA has invoked new enforcement authority for postmarking requirements granted under the 2007 FDA Amendments Act (FDAAA) and may signal a new agency trend, a legal expert says.